188 related articles for article (PubMed ID: 34731334)
1. Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons.
Wang X; He Q; Wen D; Ma L; You C
Neurol Sci; 2022 Apr; 43(4):2751-2758. PubMed ID: 34731334
[TBL] [Abstract][Full Text] [Related]
2. Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomized clinical trials.
Zhu C; Guan J; Xiao H; Luo W; Tong R
Medicine (Baltimore); 2019 Dec; 98(52):e18483. PubMed ID: 31876735
[TBL] [Abstract][Full Text] [Related]
3. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis.
Wang X; Wen D; He Q; You C; Ma L
J Headache Pain; 2022 Sep; 23(1):105. PubMed ID: 36071388
[TBL] [Abstract][Full Text] [Related]
5. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.
Cullum CK; Do TP; Ashina M; Bendtsen L; Hugger SS; Iljazi A; Gusatovic J; Snellman J; Lopez-Lopez C; Ashina H; Amin FM
J Headache Pain; 2022 Jun; 23(1):61. PubMed ID: 35655137
[TBL] [Abstract][Full Text] [Related]
6. Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials.
Gui T; Li H; Zhu F; Wang Q; Zhou X; Xue Q
Headache; 2022 Nov; 62(10):1281-1292. PubMed ID: 36373822
[TBL] [Abstract][Full Text] [Related]
7. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.
Ornello R; Casalena A; Frattale I; Gabriele A; Affaitati G; Giamberardino MA; Assetta M; Maddestra M; Marzoli F; Viola S; Cerone D; Marini C; Pistoia F; Sacco S
J Headache Pain; 2020 Apr; 21(1):32. PubMed ID: 32264820
[TBL] [Abstract][Full Text] [Related]
8. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of galcanezumab for migraine: evidences from direct and indirect comparisons.
Wang X; Song J; You C
Int J Neurosci; 2023 Dec; 133(8):925-933. PubMed ID: 35815440
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis.
Wang X; Chen Y; Song J; You C
Front Pharmacol; 2021; 12():649143. PubMed ID: 33867991
[No Abstract] [Full Text] [Related]
11. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study.
Reuter U; Goadsby PJ; Ferrari MD; Da Silva Lima GP; Mondal S; Kalim J; Hasan F; Wen S; Arkuszewski M; Pandhi S; Stites T; Lanteri-Minet M
Neurology; 2024 May; 102(10):e209349. PubMed ID: 38669638
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials.
Lampl C; Kraus V; Lehner K; Loop B; Chehrenama M; Maczynska Z; Ritter S; Klatt J; Snellman J
J Headache Pain; 2022 Aug; 23(1):104. PubMed ID: 35978286
[TBL] [Abstract][Full Text] [Related]
13. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.
Lattanzi S; Brigo F; Trinka E; Vernieri F; Corradetti T; Dobran M; Silvestrini M
Drugs; 2019 Mar; 79(4):417-431. PubMed ID: 30793254
[TBL] [Abstract][Full Text] [Related]
14. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.
Ornello R; Baraldi C; Guerzoni S; Lambru G; Andreou AP; Raffaelli B; Gendolla A; Barbanti P; Aurilia C; Egeo G; Cevoli S; Favoni V; Vernieri F; Altamura C; Russo A; Silvestro M; Valle ED; Mancioli A; Ranieri A; Alfieri G; Latysheva N; Filatova E; Talbot J; Cheng S; Holle D; Scheffler A; Nežádal T; Čtrnáctá D; Šípková J; Matoušová Z; Casalena A; Maddestra M; Viola S; Affaitati G; Giamberardino MA; Pistoia F; Reuter U; Sacco S
J Headache Pain; 2022 Mar; 23(1):38. PubMed ID: 35305579
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Cheng S; Numachi Y; Peng C; Xue F; Mikol DD
Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538
[TBL] [Abstract][Full Text] [Related]
16. Optimal Dose of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Meta-Analysis.
Yang Y; Chen M; Wu D; Sun Y; Jiang F; Chen Z; Wang Z
Curr Neuropharmacol; 2022; 20(2):460-470. PubMed ID: 34429056
[TBL] [Abstract][Full Text] [Related]
17. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
Garland SG; Smith SM; Gums JG
Ann Pharmacother; 2019 Sep; 53(9):933-939. PubMed ID: 30813769
[No Abstract] [Full Text] [Related]
18. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
19. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Safety and Effectiveness of Erenumab in Patients with Migraine: A Systematic Review and Single-Arm Meta-analysis.
Bomtempo FF; Rocha RB; Cenci GI; Nager GB; Telles JPM
Clin Drug Investig; 2023 Jan; 43(1):45-59. PubMed ID: 36482037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]